(MENAFN - Investor Brand Network) Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing innovative biological products targeting inflammation and immunology ("I&I") and offering contract development and manufacturing organization ("CDMO") services through its Scinai Bioservices division, released its financial results for the nine months ending Sept. 30, 2024. The announcement highlights the company's progress in advancing its I&I-focused pipeline and the expansion of its CDMO operations, showcasing its commitment to delivering high-quality biologics and fostering strategic partnerships. This update reflects Scinai's efforts to strengthen its position in the biopharmaceutical and CDMO markets, aligning with its broader vision of growth and innovation.

To view the full press release, visit

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology ("I&I") biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies ("NanoAbs") targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company's website at
.

NOTE TO INVESTORS:
The latest news and updates relating to SCNI are available in the company's newsroom at

About BioMedWire

BioMedWire
("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,"Biotech" to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN22112024000224011066ID1108915595

COMTEX_460099310/2604/2024-11-23T01:55:18